

NOVOGEN LIMITED
ASX:NRT



ASX RELEASE

15 November 2013

Novogen Ltd (ASX: NRT) today announced to the market that it has, subject to the passing of the resolutions put to the AGM to be held today, agreed to issue a third convertible security pursuant to the convertible security agreement it entered into in July 2013. The Convertible Security will provide the Company with A\$2 million immediately.

The Convertible Security Agreement disclosed in our release of 4 July 2013 has also been amended in that subject to sufficient headroom under chapter 7 of the listing rules, the maximum which may be drawn has been increased to \$8 million, the maximum tranche has been increased to \$2 million, restrictions on conversion of the convertible security have been lifted and for this Convertible Security only, the threshold for the right of Novogen to require the conversion of the Convertible Security is lifted from \$0.28 to the greater of \$0.35 and 130% of the daily VWAP for the 20 consecutive days prior to the issue of the Convertible Security.

Dr Graham Kelly, Novogen CEO, said,

"The Company's R&D program is expanding as expected and this exercise of a third Convertible Security will provide the capital to underwrite that program. The recent discovery of activity by one of the Company's drug families in degenerative disease adds an entirely new and exciting dimension that we are anxious to progress."

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies - the super-benzopyran chemical family and anti-tropomyosin drug technology.

Contact details

Dr Graham Kelly, Chief Executive Officer
Tel: 61 2 9476 0344
Fax: 61 2 9476 0388
Mobile: (61) 0429 854 390



16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA
PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA

Email: graham.kelly@novogen.com

Web: www.novogen.com